December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Tom Powles: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC
Dec 10, 2024, 13:49

Tom Powles: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC

Tom PowlesProfessor at the University of London, posted the following on X:

“1/3 TROPICS-4: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC.

OS & PFS HR of 0.86, not significance. RR 23 vs 14, but G3+ TRAE 67 vs 35% with G5 TRD. While there is activity, the toxicity and lower RR compared to EV/erda were problematic.

Debate about whether lack of prophylactic GCSF was responsible. But Deaths were still seen with GCSF prophylaxis. Heavily pretreated bladder cancer is a tough place to do trials due to comorbidities. This maybe different in other cancers and even in earlier bladder cancer.

Is this the end of SG or TROP-2/TOPO1 ADCs in UC? It’s tough for SG and FDA withdrawal is justified, but studies show SG activity. It would be a shame to drop this class altogether. Other TROP2/TOPO1 ADCs (D-DXD, MK2870) may have a different tox due to linker.”

Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals.

His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.

More posts featuring Tom Powles.